Several anti‐angiogenic agents have been approved for clinical use in HCC, including the anti‐VEGF antibody bevacizumab that is co‐administered with the anti‐PD‐L1 antibody atezolizumab. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.